Article

Treatment of critically ill patients with candidemia.

Infectious Diseases Department, Hospital Clínico, Barcelona, Spain.
International Journal of Antimicrobial Agents (Impact Factor: 4.42). 11/2008; 32 Suppl 2:S93-7. DOI: 10.1016/S0924-8579(08)70007-4
Source: PubMed

ABSTRACT Early initiation of effective antimicrobial therapy is crucial for the prognosis of any infection, especially in the critically ill patient. This is particularly true in the case of candidemia. However, the earlier an empirical antimicrobial regimen is started, the greater the probability of diagnostic error and the possibility of side-effects. Recent experience of the clinical efficacy and good tolerance of echinocandins in the treatment of candidemia obliges us to review the indications for empirical antifungal treatment and the choice of antifungal agent in the critically ill patient.

0 Bookmarks
 · 
68 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Candida albicans infections have become increasingly recognised as being biofilm related. Recent studies have shown that there is a relationship between biofilm formation and poor clinical outcomes in patients infected with biofilm proficient strains. Here we have investigated a panel of clinical isolates in an attempt to evaluate their phenotypic and transcriptional properties in an attempt to differentiate and define levels of biofilm formation.
    BMC Microbiology 07/2014; 14(1):182. · 2.98 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objetivo: Determinar cuál de los antimicóticos disponibles en el cuadro básico del Instituto Mexicano del Seguro Social (anfotericina B, fluconazol, voriconazol, caspofungina) y de otros que no se encuentran actualmente en el mismo, como anidulafungina y anfotericina B liposomal, sería la terapia más coste-efectiva para el tratamiento de la candidiasis invasiva en pacientes adultos (>18 años) no neutropénicos en estado crítico, atendidos en Unidad de Cuidados Intensivos (UCI), desde la perspectiva del proveedor de servicios públicos de salud (IMSS). Métodos: Evaluación económica de coste-efectividad. Se elaboró un modelo de árbol de decisiones con un horizonte temporal de 12 semanas. Las medidas de efectividad fueron el éxito clínico sin eventos adversos, la supervivencia y los días de estancia en la UCI. Se realizó un análisis de sensibilidad probabilístico con una simulación de Monte Carlo de primer orden. Resultados: Anidulafungina tuvo los costes más bajos (26.516,76$ USD) en tanto que anfotericina B fue el que tuvo los costes más altos (34.507,62$ USD). La opción con mayor éxito clínico sin efectos colaterales fue la de anidulafungina (58,8%). La supervivencia más alta se observó con anidulafungina (88,8%) y anfotericina B liposomal (86,1%). Por lo anterior, anidulafungina podría ahorrar, en promedio, cerca de tres días de estancia en la UCI y resultó ser la opción más coste-efectiva. Conclusiones: En el IMSS sería una buena elección seleccionar la anidulafungina como un tratamiento inicial para el manejo de los pacientes con candidiasis invasiva, lo cual aportaría importantes ahorros al sistema de atención médica.
    Pharmacoeconomics - Spanish Research Articles 8(1).
  • [Show abstract] [Hide abstract]
    ABSTRACT: Fungal infections are common in critically ill patients and are associated with increased morbidity and mortality. Candida spp are the most commonly isolated fungal pathogens. The last 2 decades have seen an increased incidence of fungal infections in critical illness and the emergence of new pathogenic fungal species and also the development of more effective (better bioavailability) and safer (less toxicity, fewer drug interactions) drugs. The distinction between colonization and infection can be difficult, and problems diagnosing infection may delay initiation of antifungal treatment. A number of factors have been identified that can help to distinguish patients at high risk for fungal infection. The antifungal agents that are most frequently used in the intensive care unit are the first- and second-generation azoles and the echinocandins; amphotericin B derivatives (mainly the liposomal agents) are less widely used because of adverse effects. The choice of antifungal agent in critically ill patients will depend on the aim of therapy (prophylaxis, pre-emptive, empiric, definitive), as well as on local epidemiology and specific properties of the drug (antifungal spectrum, efficacy, toxicity, pharmacokinetic/pharmacodynamic properties, cost). In this article we will review all these aspects and propose an algorithm to guide selection of antifungal agents in critically ill patients.
    Journal of critical care 10/2013; 28(5):717-27. · 2.13 Impact Factor